Introduction

Poland's economy has grown from strength to strength in the past 5 years, and despite the global economic downturn Poland is expected to maintain positive growth through 2010. However, concern exists over intellectual property and inconsistent drug reimbursement. Nevertheless the strong growth of the hospital and retail sectors is encouraging for both foreign and domestic Pharma.

Scope

• Provides an overview of the evolving demographics of Poland
• In-depth assessment of its healthcare and regulatory system and the challenges that branded Pharma face
• Insight into of the competitive dynamics of both the hospital and retail markets
• Profiles and analysis of key brands and players in the Polish market

Highlights

The Polish government is undertaking structural reforms with the aid of EU funding to improve internal infrastructure in an effort to attract more foreign investment. However, Poland needs to address its regulatory process and get up to speed both implementing and enforcing EU pharmaceutical legislation.

The cardiovascular and central nervous system markets in addition to those for other chronic diseases are forecast to experience significant further growth driven by the growing prevalence of these diseases among the increasingly aging population.

The growth of the Polish oncology hospital market is in part attributed to the significant funding this area has received from the government, with other chronic diseases expected to benefit as the government expands its therapeutic programs into other areas.

Reasons to Purchase

• Understand the Polish healthcare market and the strategic implications of future reforms and how these will affect your business
• Identify the opportunities ad barriers for entering the Polish market, plus growth drivers and resistors for established domestic and foreign players
• Gain insight into the evolving dynamics of the Polish retail and hospital pharmaceutical market